When the U.S. economy was on the cusp of falling into an abyss in late 2008, companies across the nation collectively decided to cut all unnecessary spending. An uncertain road ahead meant it was time to preserve cash.
Of course, these companies eventually loosened up, and as we've seen in the past four years, have been buying back massive amounts of their own stock while doling out ever-higher dividends.
But there is one area that companies remain quite conservative: capital spending, also known as capital investment or capital expenditures (or capex, for short).
Although capital spending has moved up from the crisis-era lows, it still remains far below typical levels. Analysts at Goldman Sachs who have studied the spending patterns see "the U.S. reaching a near 50-year low in private non-residential fixed investment when measured against GDP." These analysts believe it would take a $150 billion increase to bring capital investments back in line with historical norms.
10 Best Telecom Stocks To Watch Right Now: GenMark Diagnostics Inc.(GNMK)
GenMark Diagnostics, Inc. operates as a molecular diagnostics company primarily in the United States. It focuses on the development and commercialization of multiplexed molecular diagnostic testing systems for the detection and measurement of DNA and RNA targets used in the treatment of patients. The company?s products comprise eSensor XT-8 system, an automated molecular diagnostic system, which enable reference laboratories and hospitals to perform molecular diagnostic tests; and eSensor XT-8 Cartridge that utilizes a microfluidic system to accelerate target binding and enhance time to result. It also offers IVD tests, including eSensor cystic fibrosis genotyping test, eSensor thrombophilia risk test, and eSensor warfarin sensitivity test. The company?s other multiplexed molecular diagnostic tests pipeline under development comprise eSensor 2C19 test for the multiplexed detection and genotyping of various alleles of the cytochrome P450 (CYP450) 2C19 gene locus; eSensor respiratory viral panel, a nucleic acid multiplex test for the simultaneous detection and identification of multiple respiratory virus nucleic acids and mutations that confer resistance of Influenza A to the anti-viral drug Oseltamivir (Tamiflu); and eSensor KRAS/BRAF test for the multiplexed detection and genotyping of 12 mutations in codons 12 and 13 of KRAS and the V600E mutation in BRAF. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Advisors' Opinion:- [By Roberto Pedone]
GenMark Diagnostics (GNMK) is a molecular diagnostics company, engages in the development, manufacturing, marketing, sale, and support of instruments and molecular tests based on its proprietary eSensor detection technology in the U.S. This stock closed up 1.7% to $9.89 in Tuesday's trading session.
Tuesday's Range: $9.24-$9.95
52-Week Range: $6.38-$16.00
Thursday's Volume: 562,000
Three-Month Average Volume: 385,008From a technical perspective, GNMK bounced modestly higher here with above-average volume. This stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $8.75 on the downside and $10.71 on the upside. This bounce is starting to push GNMK within range of triggering a near-term breakout trade above the upper-end of its sideways trading chart pattern. That breakout will hit if GNMK manages to clear some near-term overhead resistance levels at $10.04 to $10.50 and then once it takes out more resistance at $10.71 with high volume.
Traders should now look for long-biased trades in GNMK as long as it's trending above Tuesday's low of $9.24 or around $9 and then once it sustains a move or close above those breakout levels with volume that hits near or above 385,008 shares. If that breakout triggers soon, then GNMK will set up to re-test or possibly take out its next major overhead resistance levels at $12 to $13.50.
- [By Sean Williams]
What: Shares of GenMark Diagnostics (NASDAQ: GNMK ) , a molecular diagnostics company, slumped as much as 10% after updating its full-year revenue guidance after the bell last night.
Best Prefered Stocks To Buy For 2014: AutoNation Inc (AN)
AutoNation, Inc. (AutoNation), incorporated on May 30, 1991, is an automotive retailer in the United States. As of December 31, 2011, the Company had three operating segments: Domestic, Import, and Premium Luxury. As of December 31, 2011, it owned and operated 258 new vehicle franchises from 215 stores located in the United States, predominantly in metropolitan markets in the Sunbelt region. Its stores sell 32 different brands of new vehicles. The core brands of vehicles that it sells, representing approximately 90% of the new vehicles that it sold during the year ended December 31, 2011, was manufactured by Ford, Toyota, Nissan, General Motors, Honda, Mercedes-Benz, BMW, and Chrysler. The Company offers a diversified range of automotive products and services, including new vehicles, used vehicles, parts and automotive repair and maintenance services , and automotive finance and insurance products, which includes the arranging of financing for vehicle purchases through third-party finance sources. The Company retailed approximately 400,000 new and used vehicles through its stores in 2011. It acquired one automotive retail franchise and related assets during 2011.
Domestic segment consists of retail automotive franchises that sell new vehicles manufactured by General Motors, Ford, and Chrysler. Its Import segment is comprised of retail automotive franchises that sell new vehicles manufactured primarily by Toyota, Honda, and Nissan. Its Premium Luxury segment is consists of retail automotive franchises that sell new vehicles manufactured primarily by Mercedes-Benz, BMW, and Lexus. The franchises in each segment also sells used vehicles, parts and automotive repair and maintenance services, and automotive finance and insurance products. For the year ended December 31, 2011, Domestic revenue represented 34% of total revenue, Import revenue represented 37% of total revenue, and Premium Luxury revenue represented 28% of total revenue. Corporate and other is consist of its other businesses, incl! uding collision centers, e-commerce activities, and an auction operation, each of which generates revenues, as well as unallocated corporate overhead expenses and retrospective commissions for certain financing and insurance transactions that it arranges under agreements with third parties.
The Company�� stores acquires vehicles for retail sale either directly from the applicable automotive manufacturer or distributor or through dealer trades with other stores of the same franchise. it acquires used vehicles from customer trade-ins, auctions, lease terminations, and other sources. It recondition used vehicles acquired for retail sale at its stores��service facilities and capitalize costs related thereto as used vehicle inventory. Through its VVOs, which are located on existing store facilities, it sells vehicles that it would have traditionally wholesaled with an average retail price lower than that of used vehicles it typically retail. Used vehicles that the Company do not sell at its stores or VVOs generally are sold at wholesale prices through auctions.
The Company offers a variety of automotive finance and insurance products to its customers. The Company arranges for its customers to finance vehicles through installment loans or leases with third-party lenders, including the vehicle manufacturers��and distributors��captive finance subsidiaries, in exchange for a commission payable to the Company. It also offers its customers various vehicle protection products, including extended service contracts, maintenance programs, guaranteed auto protection (GAP, this protection covers the shortfall between a customer�� loan balance and insurance payoff in the event of a casualty), tire and wheel protection, and theft protection products. The vehicle protection products that its stores offers to customers are underwritten and administered by independent third parties, including the vehicle manufacturers��and distributors��captive finance subsidiaries. The Company sells t! he produc! ts on a straight commission basis; however, it also participate in future underwriting profit for certain products pursuant to retrospective commission arrangements. Commissions that it receives from these third-party providers may be subject to chargeback, in full or in part, if products that it sells, such as extended service contracts, are cancelled. Its stores also provide a range of vehicle maintenance, repair, paint, and collision repair services, including warranty work that can be performed only at franchised dealerships and customer-pay service work. The Company has entered into framework agreements with vehicle manufacturers and distributors. It operates each of its new vehicle stores under a franchise agreement with a vehicle manufacturer or distributor.
Advisors' Opinion:- [By Lawrence Meyers]
For auto loans, debt balance and number of accounts are also increasing, while auto loan delinquencies are declining. That makes automakers great stocks to buy. Trucks and used cars are selling best right now, so I�� choose the all-American Ford (F) which has regained its footing post-financial crisis, and the king of used car retailers, AutoNation (AN).
- [By Ben Levisohn]
They did, however, show passion for Autonation (AN), which gained 3.1% to $46.76, benefiting, I suppose, from demand for Ford’s (F) Fusion. Biotech stocks continued their strong run today. Biogen (BIIB) gained 2.1% to $214.13, while Celgene (CELG) rose 2.5% to $142.58.
- [By Michael Lewis]
Part of this year-over-year growth is attributed to the 10 new stores opened throughout the year -- the most since 2008. As part of this growth, SG&A costs rose more than 10% to $1 billion. Marketing campaigns are incredibly important for the company to stay competitive with peers such as AutoNation (NYSE: AN ) , but investors need to keep an eye on these SG&A increases to make sure they are yielding an appropriate return on the sales front.
Best Prefered Stocks To Buy For 2014: XenoPort Inc.(XNPT)
XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing internally discovered product candidates that utilize the body?s natural nutrient transport mechanisms to enhance the therapeutic benefits of drugs. The company licenses its lead product candidate Gabapentin Enacarbil, a transported prodrug of gabapentin, to Astellas Pharma Inc. in Japan and five Asian countries, as well as to Glaxo Group Limited in the United States. Astellas Pharma Inc. filed new drug application for the approval of Gabapentin Enacarbil as a treatment for restless legs syndrome in Japan. The company also develops Arbaclofen Placarbil, which completed a Phase II clinical trial for the treatment of spasticity in patients with spinal cord injury. In addition, it develops Arbaclofen Placarbil for the treatment of gastroesophageal reflux disease. Further, the company develops XP21279, which is in Phase II clinical trial for the treatment of Parkinson?s disease; and XP2382 9, a novel prodrug of methylhydrogenfumarate that is in preclinical stage. It has strategic alliances with Astellas Pharma, Inc. and Glaxo Group Limited. The company was founded in 1999 and is based in Santa Clara, California.
Advisors' Opinion:- [By Sean Williams]
Shareholders of XenoPort (NASDAQ: XNPT ) are also glad for the long weekend after their stock tumbled this week following disappointing late-stage results for Arbaclofen Placarbil, or AP. Aimed at treating spasticity in patients with multiple sclerosis, AP was unsuccessful in delivering a statistically significant benefit compared to the placebo. XenoPort's management noted that the company plans to cease development of AP and instead focus on the commercial development of recently approved restless leg syndrome drug Horizant, and its remaining clinical pipeline.
- [By Monica Gerson]
Breaking news
Acceleron Pharma (NASDAQ: XLRN) today announced that it has commenced an underwritten public offering of $100 million of its common stock. To read the full news, click here. XenoPort (NASDAQ: XNPT) announced today that it intends to offer and sell 10,000,000 shares of its common stock, subject to market and other conditions, in an underwritten public offering. To read the full news, click here. Affymetrix (NASDAQ: AFFX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its CytoScanåº Dx Assay. To read the full news, click here. Verizon Communications (NYSE: VZ) and Intel (NASDAQ: INTC) today announced an agreement for Verizon to purchase from Intel the assets of Intel Media, a business division dedicated to the development of Cloud TV products and services. To read the full news, click here.Posted-In: Evercore Partners US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets
- [By Max Macaluso, Ph.D.]
Treatments for RLS
While a better understanding of RLS and its long-term impact on health are needed, there are FDA-approved drugs available to treat the symptoms of this disorder. GlaxoSmithKline (NYSE: GSK ) brought a RLS drug, Requip, to market eight years ago, and the drug was also approved for Parkinson's disease. Total sales of the medication have been falling in recent years due to generic competition and reached only 164 million pounds ($257.5 million) in 2012. Until recently, GSK also had a second RLS drug called Horizant in collaboration with biotech company XenoPort (NASDAQ: XNPT ) . GSK recently handed the rights to the drug back to XenoPort after sales failed to meet its expectations, and the biotech is now commercializing the drug alone. - [By CRWE]
XenoPort, Inc. (Nasdaq:XNPT) reported that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin clinical studies of XP23829 as a potential treatment for relapsing-remitting multiple sclerosis (RRMS).
Best Prefered Stocks To Buy For 2014: Burberry Group PLC (BRBY)
Burberry Group plc (Burberry) is a holding company. The Company designs and sources luxury apparel and accessories, selling through a diversified network of retail (including digital), wholesale and licensing channels worldwide. The Company�� Retail/wholesale channel is engaged in the sale of luxury goods through Burberry mainline stores, concessions, outlets and digital commerce, as well as Burberry franchisees, prestige department stores globally and multi-brand specialty accounts. The Company�� retail channel includes approximately 206 mainline stores, 214 concessions within department stores, digital commerce and 49 outlets. The Company�� wholesale channel includes sales to department stores, multi-brand specialty accounts, Travel Retail and franchisees who operates approximately 65 Burberry stores. Advisors' Opinion:- [By Jonathan Morgan]
Burberry (BRBY) added 1.8 percent to 1,488 pence. Revenue climbed 17 percent to 1.03 billion pounds, while adjusted pretax profit for the six months ended Sept. 30 rose to 174 million pounds from 173 million pounds a year earlier, the London-based trenchcoat maker said in a statement.
- [By Sofia Horta e Costa]
Commodity producers slid as the release fueled concern about the slowdown in the world�� second-biggest economy. Burberry Group Plc (BRBY) gained 4.8 percent after the company�� spring-summer collection helped increase retail sales in its fiscal first quarter by more than analysts had estimated. Tryg A/S (TRYG) added 3.3 percent after posting better-than-forecast pretax profit as cost cuts offset increased weather-related claims.
Best Prefered Stocks To Buy For 2014: New York & Company Inc.(NWY)
New York & Company, Inc., together with its subsidiaries, operates as a specialty retailer of women's fashion apparel and accessories in the United States. The company offers a range of wear-to-work, and casual apparel and accessories, including pants, jackets, knit tops, blouses, sweaters, denim, T-shirts, activewear, handbags, and jewelry. It sells its products under the New York & Company, Lerner, Lerner New York, New York Style, City Stretch, City Style, and NY&C brand names. The company sells its branded merchandise through its network of retail stores and E-commerce store at nyandcompany.com. As of March 15, 2012, it operated 532 stores in 43 states. The company, formerly known as NY & Co. Group, Inc., was founded in 1918 and is headquartered in New York, New York.
Advisors' Opinion:- [By Anna Prior]
New York & Co(NWY).’s fiscal third-quarter loss narrowed as the women’s apparel retailer recorded comparable-store-sales growth and benefited from lower costs.
- [By Sue Chang]
New York & Co. (NWY) �is likely to post earnings of 10 cents a share in the fourth quarter.
- [By Jeremy Bowman]
What: Shares of New York & Company (NYSE: NWY ) were looking sharp, gaining as much as 10% two market days after reporting earnings, as Janney Montgomery Scott today reaffirmed its buy rating and upped its price target by 50% to $6.
No comments:
Post a Comment